Virco News

HIV-1 ARV Resistance Testing: Practical Tools and Case Histories in Therapy Management Virco organized a symposium entitled HIV-1 ARV Resistance Testing: Practical Tools and Case Histories in Therapy Management in Rome on March 11, 2004. The symposium took place just prior to the 2nd European HIV Drug Resistance Workshop...

Virco established a Technical Advisory Board February 8, 2004 Virco recently established a Technical Advisory Board , which held an inaugural meeting in San Francisco on February 8 2004, just prior to the Retrovirus conference. The members of the Technical Advisory Board are: Dr. Calvin Cohen (Harvard Medical School,...

Vth Brazilian Symposium of HIV Research Rio de Janeiro, Brazil - November 23-26, 2003 On Tuesday 25th, Virco organized a satellite lunch symposium entitled "A review of HIV Resistance Testing and an Introduction to Virtual Phenotype™". Topics that were discussed during this 1.5-hour symposium are "review of the current...

Virco announced the introduction of two newly approved drugs, Atazanavir (Reyataz) and Emtricitabine (FTC, Emtriva) on the VirtualPhenotype™ report November 2003 Virco announced the introduction of two newly approved drugs, Atazanavir (Reyataz™) and Emtricitabine (FTC, Emtriva™) on the Virtual Phenotype™ report. From November 24th onwards, each Virtual Phenotype™ report...

9th European AIDS Conference http://www.eacs-conference2003.com/intro.html Warsaw, Poland - October 25-29, 2003 Virco had a booth at the commercial exhibition, and presented two posters. (a) bacheler_warsaw_poster.pdf & bacheler_warsaw_abstract.pdf In this poster, Dr. Bacheler and colleagues report that certain rare mutations cause high level NNRTI resistance and they identify a new...

43rd Annual ICAAC http://www.icaac.org/ICAAC.asp Chicago, Sept. 14-17 2003 Virco had a commercial exhibition booth at the 43rd Annual ICAAC meeting, and presented 3 posters. (a) bacheler_chicago_poster.pdf In this poster Bacheler and colleagues report on HIV-1 resistance trends between 1998 and 2002. The Virco database was used to do analyses...

Virco announced the launch of version 3.3.00 of the VirtualPhenotype™ August 2003 Virco announced the launch of version 3.3.00 of the Virtual Phenotype™. This new version includes: (a) an update of the list of resistance-associated mutations and combinations of mutations that are considered when a sample's mutational profile is...

2nd IAS conference on HIV pathogenesis and treatment (1) Paris, July 13-16, 2003 Virco presented three posters at this meeting and had a booth at the commercial exhibition. (a) van_houtte_paris_abstract.pdf & van_houtte_paris_poster.pdf For this poster the genotype-phenotype database was queried for the prevalence of specific combinations of NAMs and...

2nd IAS conference on HIV pathogenesis and treatment (2) During the conference virco organized two lunchtime satellite symposia. (a) The first symposium, on July 15th, was targeted towards existing virco customers and users of the Antivirogram® and Virtual Phenotype™ services. The session was moderated by Dr. Dan Kuritzkes (Harvard...

XII International HIV Drug Resistance Workshop http://www.informedhorizons.com/resistance2003/ June 10-14, Los Cabos Mexico Webcast with conferences highlights is available from the conference website. Virco had three posters at this workshop: (a) van_houtte_mexico_poster.pdf & van_houtte_mexico_abstract.pdf This poster used Virco's extensive genotype/phenotype database to analyse the prevalence and phenotypic resistance patterns of...